A股異動 | 常山北明漲逾8% 子公司推出微審批平台 助力線上政務
格隆匯2月14日丨常山北明(000158.SZ)現報8.15元,漲8.09%,暫成交4.5億元,最新總市值130億元。據悉,新冠肺炎疫情發生後,常山北明子公司北明軟件推出微審批平台,通過實名認證和人工智能技術,可實現企業或羣眾辦事無需到辦事大廳就能完成業務辦理的效果,如線上辦理營業執照、企業登記檔案查詢打印等,可大幅提升辦事效率,阻斷疫情傳播。目前該線上政務平台已在濟南、青島等地區的相關政府部門成功應用。此外,北明軟件研發並上線了互聯網庭審小程序“互聯網開庭”平台,在疫情防控期間向全國法院和仲裁委以及全國的勞動人事爭議仲裁院免費開放。目前,江蘇、陝西、重慶等地法院紛紛上線。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.